Mutational alterations of the p16CDKN2A tumor suppressor gene have low incidence in mesenchymal chondrosarcoma

Dae Kyung Bae, Yong Koo Park, Sung Gil Chi, Chun Woo Lee, K. Krishnan Unni

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Mutational inactivation of the cyclin-dependent kinase inhibitors (CDKIs) (p16INK4A/MTS1) tumor suppressor gene has been found in a variety of human tumor types. To investigate the involvement of CDKI abnormality in mesenchymal chondrosarcoma, alterations of CDKIs were examined in human mesenchymal chondrosarcoma tissues using a quantitative DNA/ PCR, PCR-SSCP. Seven of 33 specimens (21.2%) showed abnormally low levels of p16CDKN2A amplification, suggesting that the allelic deletion of the gene might be a less frequent event in progression of this tumor. To detect subtle sequence alterations such as point mutations, SSCP analysis of the entire coding region of the p16CDKN2A gene, exons 1, 2, and 3 regions, showed no altered SSCP patterns in 33 mesenchymal chondrosarcoma specimens. A low incidence of genetic alterations of the p16CDKN2A was found in mesenchymal chondrosarcoma. Through this study, we conclude that alteration of the p16CDKN2A gene does not participate significantly in the tumorigenesis of mesenchymal chondrosarcoma.

Original languageEnglish
Pages (from-to)5-10
Number of pages6
JournalOncology Research
Issue number1
Publication statusPublished - 2000
Externally publishedYes


  • Mesenchymal chondrosarcoma
  • p16 tumor suppressor gene

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Mutational alterations of the p16CDKN2A tumor suppressor gene have low incidence in mesenchymal chondrosarcoma'. Together they form a unique fingerprint.

Cite this